Sign in

    Nishan Sarna

    Vice President and Equity Research Analyst at Citigroup

    Nishan Sarna is a Vice President and Equity Research Analyst at Citigroup, specializing in the coverage of the industrial sector with a focus on large-cap machinery, engineering, and industrial technology companies such as Caterpillar, Deere & Company, and Cummins. With a strong background in financial analysis and valuation, Sarna is recognized for insightful company-specific recommendations and has achieved robust forecast accuracy on platforms like TipRanks, maintaining an estimated success rate of around 65% with consistent outperformance compared to sector peers. He began his career as an investment banking analyst at Barclays before joining Citi in 2018, where he has advanced through various research roles. Nishan holds FINRA Series 7 and Series 63 licenses, underlining his commitment to professional standards and industry best practices.

    Nishan Sarna's questions to BioNTech (BNTX) leadership

    Nishan Sarna's questions to BioNTech (BNTX) leadership • Q1 2025

    Question

    Nishan Sarna, on behalf of Geoff Meacham, asked about the key factors and rationale driving the selection of specific combination therapies, such as ADCs and cell therapies, to be paired with BNT327.

    Answer

    CEO Ugur Sahin detailed a three-part strategy: 1) combining with other IO pipeline assets like bispecifics, 2) combining with mRNA vaccines to target residual disease, and 3) combining with their ADC portfolio to reduce tumor burden and leverage immunogenic cell death, a concept for which they have preclinical proof of concept.

    Ask Fintool Equity Research AI